Jaume Mora, Sara Perez-Jaume, Amalia Varo, Margarida Simao, Alicia Castaneda Heredia, Saray Chamorro, Juan Pablo Muñoz, Maite Gorostegui, Sandra Lopez, Cristina Larrosa. "Irinotecan, temozolomide and naxitamab plus GM-CSF (HITS) and naxitamab plus GM-CSF and ifosfamide, carboplatin, etoposide (NICE) for patients with relapsed or refractory high-risk neuroblastoma: A single center, open-label phase 2 clinical trial.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.10039